Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Oluyomi M. Bakare"'
Autor:
Clare Zhu, Prashant Donthamsetti, Ravi Kumar Verma, Thomas M. Keck, Oluyomi M. Bakare, Hideaki Yano, Amy Hauck Newman, Jeffrey R. Deschamps, Lei Shi, Comfort A. Boateng, Michael P. Ellenberger, Vivek Kumar, Mayako Michino, Alessandro Bonifazi, Jonathan A. Javitch
Publikováno v:
Journal of Medicinal Chemistry. 60:580-593
Both dopamine D3 receptor (D3R) partial agonists and antagonists have been implicated as potential medications for substance use disorders. In contrast to antagonists, partial agonists may cause fewer side effects since they maintain some dopaminergi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c2616d35ba39dc4074c60599fea9f48
https://doi.org/10.1021/acs.jmedchem.6b01148
https://doi.org/10.1021/acs.jmedchem.6b01148
Autor:
Caitlin Burzynski, Rana Rais, Comfort A. Boateng, Amy Hauck Newman, Oluyomi M. Bakare, Thomas M. Keck, Elie Pommier, Jonathan A. Javitch, Zheng-Xiong Xi, Jia Zhan, Barbara S. Slusher, Prashant Donthamsetti, Ashwini K. Banala
Publikováno v:
Journal of Medicinal Chemistry
The dopamine D3 receptor (D3R) is a promising target for the development of pharmacotherapeutics to treat substance use disorders. Several D3R-selective antagonists are effective in animal models of drug abuse, especially in models of relapse. Nevert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34dbb10e40377b8965f9aed3b6766a60
https://doi.org/10.1021/acs.jmedchem.5b00776
https://doi.org/10.1021/acs.jmedchem.5b00776
Autor:
Hideaki Yano, Alessandro Bonifazi, Claus J. Loland, Guo Hua Bi, Caitlin Burzynski, Oluyomi M. Bakare, Jianjing Cao, Amy Hauck Newman, Rana Rais, Rachel D. Slack, Barbara S. Slusher, Theresa A. Kopajtic, Yi He, Michael P. Ellenberger, Zheng-Xiong Xi
Publikováno v:
Journal of medicinal chemistry. 59(23)
The development of pharmacotherapeutic treatments of psychostimulant abuse has remained a challenge, despite significant efforts made toward relevant mechanistic targets, such as the dopamine transporter (DAT). The atypical DAT inhibitors have receiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::839a67a1bfaf9c3e42fea87d01ab1dec
https://pubmed.ncbi.nlm.nih.gov/27933960
https://pubmed.ncbi.nlm.nih.gov/27933960
Autor:
ComfortA. Boateng, Oluyomi M. Bakare, Jia Zhan, Ashwini K. Banala, Caitlin Burzynski, Elie Pommier, ThomasM. Keck, Prashant Donthamsetti, Jonathan A. Javitch, Rana Rais, Barbara S. Slusher, Zheng-Xiong Xi, Amy Hauck Newman
Publikováno v:
Journal of Medicinal Chemistry; Aug2015, Vol. 58 Issue 15, p6195-6213, 19p